Celldex Therapeutics, Inc. (CLDX)

Celldex Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-258.76	-157.86	-141.43	-112.33	-70.51
Depreciation & Amortization	3.38	3.18	3.01	2.9	3.07
Loss (Gain) From Sale of Assets	0.01	0.02	-	0	-0.02
Asset Writedown & Restructuring Costs	-	-	-	-	3.5
Loss (Gain) From Sale of Investments	-5.86	-15.75	-6.22	0.84	-3.21
Stock-Based Compensation	36.22	34.24	23.89	15.61	8.95
Other Operating Activities	-	-	-	-6.86	-1.63
Change in Accounts Receivable	-1.32	1.93	-2.28	-0.18	1.57
Change in Accounts Payable	11.03	11.63	9.38	3.12	3.65
Change in Other Net Operating Assets	4.34	-35.16	6.36	-6.85	-6.28
Operating Cash Flow	-210.95	-157.78	-107.29	-103.73	-60.91
Capital Expenditures	-2.71	-1.92	-1.82	-1.83	-1.25
Sale of Property, Plant & Equipment	-	-	-	0.07	0.03
Investment in Securities	211.79	-288.21	-103.96	91.7	-214.93
Investing Cash Flow	209.07	-290.13	-105.78	89.94	-216.16
Issuance of Common Stock	2.39	441.45	218.46	4.08	272.37
Financing Cash Flow	2.39	441.45	218.46	4.08	272.37
Net Cash Flow	0.52	-6.46	5.39	-9.71	-4.69
Free Cash Flow	-213.66	-159.7	-109.11	-105.56	-62.16
Free Cash Flow Margin	-13829.06%	-2274.89%	-1585.19%	-4478.57%	-1336.44%
Free Cash Flow Per Share	-3.22	-2.48	-2.25	-2.25	-1.45
Levered Free Cash Flow	-125.54	-91.67	-46.7	-58.03	-29.71
Unlevered Free Cash Flow	-125.54	-91.67	-46.7	-58.03	-29.71
Change in Working Capital	14.06	-21.6	13.46	-3.9	-1.05

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q